James J. O’Leary

1.7k total citations
67 papers, 1.4k citations indexed

About

James J. O’Leary is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, James J. O’Leary has authored 67 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 17 papers in Oncology and 16 papers in Immunology. Recurrent topics in James J. O’Leary's work include Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (10 papers) and HER2/EGFR in Cancer Research (7 papers). James J. O’Leary is often cited by papers focused on Immune Cell Function and Interaction (12 papers), T-cell and B-cell Immunology (10 papers) and HER2/EGFR in Cancer Research (7 papers). James J. O’Leary collaborates with scholars based in United States, Australia and United Kingdom. James J. O’Leary's co-authors include Helen M. Hallgren, Linda K. Hansen, Robert N. Haire, Mark S. Peterson, Frank V. Fossella, Duaine R. Jackola, George R. Blumenschein, Lisa Cupit, Martin Reck and Jason Pui Yin Cheung and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Finance and The Journal of Cell Biology.

In The Last Decade

James J. O’Leary

61 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James J. O’Leary United States 19 579 347 273 182 182 67 1.4k
V. Laine Finland 25 688 1.2× 344 1.0× 251 0.9× 229 1.3× 208 1.1× 66 1.7k
P G Riches United Kingdom 21 459 0.8× 191 0.6× 264 1.0× 104 0.6× 96 0.5× 70 1.2k
M C Pike United States 19 697 1.2× 220 0.6× 501 1.8× 82 0.5× 137 0.8× 32 1.6k
Gloria Vachino United States 13 460 0.8× 281 0.8× 665 2.4× 105 0.6× 150 0.8× 15 1.5k
J. C. E. Underwood United Kingdom 22 411 0.7× 435 1.3× 327 1.2× 197 1.1× 95 0.5× 64 1.9k
J Chassagne France 20 407 0.7× 420 1.2× 301 1.1× 93 0.5× 71 0.4× 74 1.5k
John H. Peters United States 20 481 0.8× 163 0.5× 273 1.0× 134 0.7× 109 0.6× 68 1.6k
Josef Friedl Austria 18 414 0.7× 424 1.2× 546 2.0× 107 0.6× 63 0.3× 44 1.6k
Susan B. Dillon United States 24 584 1.0× 234 0.7× 595 2.2× 129 0.7× 83 0.5× 41 1.7k
Weiping Zeng United States 21 780 1.3× 579 1.7× 514 1.9× 114 0.6× 320 1.8× 51 1.8k

Countries citing papers authored by James J. O’Leary

Since Specialization
Citations

This map shows the geographic impact of James J. O’Leary's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James J. O’Leary with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James J. O’Leary more than expected).

Fields of papers citing papers by James J. O’Leary

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James J. O’Leary. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James J. O’Leary. The network helps show where James J. O’Leary may publish in the future.

Co-authorship network of co-authors of James J. O’Leary

This figure shows the co-authorship network connecting the top 25 collaborators of James J. O’Leary. A scholar is included among the top collaborators of James J. O’Leary based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James J. O’Leary. James J. O’Leary is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Brinster, Clayton J., James J. O’Leary, Andrew Steven, et al.. (2023). Symptomatic carotid webs require aggressive intervention. Journal of Vascular Surgery. 79(1). 62–70. 12 indexed citations
2.
O’Leary, James J., Rebecca E. Scully, Louis L. Nguyen, et al.. (2019). Emergency intraoperative vascular surgery consultations at a tertiary academic center. Journal of Vascular Surgery. 71(3). 967–978. 7 indexed citations
3.
Tao, Ming, James J. O’Leary, Michael R. MacArthur, et al.. (2019). Insights From a Short-Term Protein–Calorie Restriction Exploratory Trial in Elective Carotid Endarterectomy Patients. Vascular and Endovascular Surgery. 53(6). 470–476. 12 indexed citations
4.
Shah, Samir K., et al.. (2018). Symptomatic carotid stenosis and ipsilateral carotid body tumor. VASA. 47(5). 424–426.
5.
Meyer, Christian P., Michael Hollis, Alexander P. Cole, et al.. (2015). Complications Following Common Inpatient Urological Procedures: Temporal Trend Analysis from 2000 to 2010. European Urology Focus. 2(1). 3–9. 8 indexed citations
6.
O’Leary, James J., et al.. (2011). Community-Centered Family Health History: A Customized Approach to Increased Health Communication and Awareness. Progress in community health partnerships. 5(2). 109–109. 1 indexed citations
7.
Woll, Penella J., et al.. (2010). Phase I study of lorvotuzumab mertansine (IMGN901) in patients with CD56-positive solid tumours. Journal of Clinical Oncology. 21. 1 indexed citations
8.
Carrigan, Christina N., Shanqin Xu, Yiwei Zhao, et al.. (2010). Abstract 5335: The antigen target of IMGN901, CD56, is expressed at significant levels in merkel cell carcinoma (MCC). Cancer Research. 70(8_Supplement). 5335–5335. 1 indexed citations
9.
10.
Fossella, Frank V., Penella J. Woll, Paul Lorigan, et al.. (2009). Clinical experience of IMGN901 (BB-10901) in patients with small cell lung carcinoma (SCLC). Journal of Thoracic Oncology. 4. 8 indexed citations
11.
Chanan‐Khan, Asher, Jeffrey L. Wolf, Mecide Gharibo, et al.. (2009). Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.. Blood. 114(22). 2883–2883. 17 indexed citations
12.
Cohen, Martin H., Steven Hirschfeld, Susan Flamm Honig, et al.. (2001). Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene. The Oncologist. 6(1). 4–11. 87 indexed citations
13.
Hansen, Linda K., Jeffrey P. Houchins, & James J. O’Leary. (1991). Differential regulation of HSC70, HSP70, HSP90α, and HSP90β mRNA expression by mitogen activation and heat shock in human lymphocytes. Experimental Cell Research. 192(2). 587–596. 62 indexed citations
14.
O’Leary, James J. & Helen M. Hallgren. (1991). Aging and lymphocyte function: a model for testing gerontologic hypotheses of aging in man. Archives of Gerontology and Geriatrics. 12(2-3). 199–218. 12 indexed citations
15.
Hallgren, Helen M., et al.. (1990). Effects of preliminary culture on the membrane microviscosity of lymphocytes from young and old donors. Microviscosity correlates with mitogenic response. Archives of Gerontology and Geriatrics. 10(1). 77–87. 9 indexed citations
16.
Jackola, Duaine R. & James J. O’Leary. (1989). Monocyte requirement for mitogen-induced aggregation of human peripheral mononuclear leukocytes in vitro. Experimental Cell Research. 184(1). 119–130.
17.
Haire, Robert N., Mark S. Peterson, & James J. O’Leary. (1988). Mitogen activation induces the enhanced synthesis of two heat-shock proteins in human lymphocytes.. The Journal of Cell Biology. 106(3). 883–891. 71 indexed citations
18.
O’Leary, James J., Duaine R. Jackola, Charu Mehta, & Helen M. Hallgren. (1985). Enhancement of mitogen response and surface marker analysis of lymphocytes from yuong and old donors after preliminary incubation in vitro. Mechanisms of Ageing and Development. 29(3). 239–253. 15 indexed citations
19.
O’Leary, James J., Charu Mehta, David J. Hall, & Andreas Rosenberg. (1980). QUANTITATION OF [3H]THYMIDINE UPTAKE BY STIMULATED HUMAN LYMPHOCYTES†. Cell Proliferation. 13(1). 21–32. 19 indexed citations
20.
O’Leary, James J.. (1960). Forward Investment Commitments of Life Insurance Companies. NBER Chapters. 325–350. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by V. Laine Breakdown of academic impact, for papers by P G Riches Breakdown of academic impact, for papers by M C Pike Breakdown of academic impact, for papers by Gloria Vachino Breakdown of academic impact, for papers by J. C. E. Underwood Breakdown of academic impact, for papers by J Chassagne Breakdown of academic impact, for papers by John H. Peters Breakdown of academic impact, for papers by Josef Friedl Breakdown of academic impact, for papers by Susan B. Dillon Breakdown of academic impact, for papers by Weiping Zeng
Rankless by CCL
2026